MedTrace Logo

Fructose Malabsorption in Northern Norway

NCT00555191 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2016-05-24

No results posted yet for this study

Summary

Different published studies has shown a possible co-variation between leakage of fructose to the great bowel and exacerbation of irritable bowel syndrome (IBS) symptoms.

The aim of the FINN trial is to study the role of fructose malabsorption in patients with IBS in order to evaluate different diagnostic criteria for fructose malabsorption and at the same time study the effect of diet treatment in this cohort of patients and estimate the prevalence of fructose malabsorption.

Conditions

  • Irritable Bowel Syndrome
  • Fructose Malabsorption

Interventions

BEHAVIORAL

diet restriction

each meal should contain less than 2 gm fructose

Sponsors & Collaborators

  • Nordlandssykehuset HF

    collaborator OTHER

  • University Hospital of North Norway

    lead OTHER

Principal Investigators

  • Jon Florholmen, MD PhD · University Hospital of North Norway, Department of Gastroenterology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00555191 on ClinicalTrials.gov